Vexev has raised $6 million in new funding to advance FDA regulatory activities and accelerate U.S. commercialization of VxWave, its AI-powered robotic vascular ultrasound platform. The new financing brings the Australian medical robotics company’s total funding to $19 million. Existing investors Blackbird Ventures, Neotribe Ventures, Startmate, and Horizon participated alongside new investors TreeArc Investment Group, TEN13, Bioshore Ventures, and Alumni Ventures.
VxWave combines robotics, AI, and ultrasound imaging to automate vascular ultrasound acquisition. The platform is initially being developed for upper-limb imaging with an initial focus on dialysis vascular access, where patients require frequent monitoring.
The company believes autonomous imaging could reduce reliance on specialist operators while making vascular imaging more consistent and accessible.
Vexev recently completed a multi-site U.S. clinical study with U.S. Renal Care. The company said VxWave achieved a 94% scanning success rate for autonomous vascular imaging when operated by non-specialist clinical staff.
Beyond dialysis access, Vexev plans to extend the platform into other vascular applications, including cardiovascular and peripheral artery disease, while developing additional clinical evidence to support future AI-enabled decision capabilities.
The financing will support regulatory activities, manufacturing scale-up, and commercialization as Vexev works toward FDA 510(k) clearance.
VxWave remains an investigational device and has not been cleared by the FDA or another regulatory authority for commercial distribution.
KEY QUOTES:
“We believe high-quality vascular imaging should be available wherever patients receive care, not only when a specialist is available. We are starting with dialysis patients because the clinical need is clear, but our vision is much broader: to build an autonomous imaging platform that helps clinicians make faster, more consistent and more informed decisions across vascular disease.”
John Carroll, Ph.D., Co-Founder and CEO of Vexev
“Having worked closely with Vexev for several years, I have seen the development of its impressive robot- and AI-based techniques for vascular imaging. The company’s initial focus on dialysis vascular access addresses an important challenge for patients and providers, and I believe this technology has the potential to bring meaningful innovation to dialysis patients with vascular access challenges.”
Dr. Anupam Agarwal, Senior Vice President for Medicine and Dean of the Marnix E. Heersink School of Medicine at the University of Alabama at Birmingham
